Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of Sumitomo PharmaLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 21, 2026, FDA's public records list Sumitomo Pharma America with 6 drug applications. The most recent is a drug application dated May 26, 2021: Myfembree.
Drug applications: 6
Records by year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
120172017Records1
20182018Records0vs 2017−1
20192019Records0vs 2018+0
320202020Records3vs 2019+3
120212021Records1vs 2020−2
20222022Records0vs 2021−1
20232023Records0vs 2022+0
20242024Records0vs 2023+0
20252025Records0vs 2024+0
20262026 to dateRecords0
Latest records
Newest first across sources; each opens the record
5 trials since 2013, 2 ongoing, by the sponsor of the products; see every authorized trial
A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral nuvisertib…Aug 28, 2023 · Pending · Nuvisertib (TP-3654) / Momelotinib
A phase 2/3, open-label, baseline-controlled, multicenter, long-term study to evaluate the safety, efficacy, and…Oct 6, 2022 · Ongoing · Vibegron (URO-901)
A multi-region, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating SEP-4199…Aug 25, 2022 · Closed · Aramisulpride-esamisulpride (SEP-4199)
A 12-month open-label extension study to evaluate the long-term safety, tolerability, and effectiveness of SEP-4199…Aug 25, 2022 · Closed · Aramisulpride-esamisulpride (SEP-4199)
A phase 1/2 open-label, dose-escalation, dose-expansion study of DSP-5336 in acute leukemia patients with and without…Feb 8, 2022 · Ongoing · Enzomenib (DSP-5336)
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $121M of it for research; see every company
$60.2M20232023Paid$60.2M
$48.1M20242024Paid$48.1Mvs 2023−$12.1M
$26.4M20252025Paid$26.4Mvs 2024−$21.7M
Orphan designations (FDA)
6 designations since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
EnzomenibTreatment of acute lymphoblastic leukemia (ALL) · Jul 19, 2026
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.